BioCentury
ARTICLE | Clinical News

Mersana gets green light to resume ADC trial, but new dosing may slow progress

September 21, 2018 4:37 PM UTC

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 on Sept. 17 seemingly in response to the trial's protocol revisions also announced that day that could delay the readout of expansion cohort data needed to resolve some investors' concerns over the death that triggered the hold.

FDA suspended new enrollment in the dose-escalation trial in July following a possibly treatment-related death at the seventh dose level. The trial is evaluating XMT-1522 to treat advanced HER2-expressing breast, gastric or non-small cell lung cancer (NSCLC) (see "Partial Clinical Hold on ADC Sinks Mersana Shares")...